Stryker, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $435.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Josh Jennings has given his Buy rating due to a combination of factors, primarily driven by Stryker’s strong financial performance in the third quarter. The company reported revenue and earnings per share (EPS) that exceeded market expectations, with organic sales growth reaching 9.5%. This growth was particularly robust in the Orthopedics and MedSurg segments, which saw increases of 11.4% and 8.4%, respectively.
Additionally, Stryker raised its full-year guidance for both organic sales growth and EPS, indicating confidence in continued operational momentum. The company’s performance was strong across various geographies, with notable growth in the U.S. and international markets such as South Korea and Japan. Despite slightly missing the Street’s forecast on gross and operating margins, the overall positive financial results and upward revision in guidance underpin Jennings’s optimistic outlook on Stryker’s stock.
According to TipRanks, Jennings is a 2-star analyst with an average return of 0.6% and a 46.39% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Medtronic, and Boston Scientific.
In another report released today, Barclays also maintained a Buy rating on the stock with a $453.00 price target.